Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A

NCT00971425 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00971425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00971425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
September 8, 2009
Completion date
October 8, 2010
Enrollment
145 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

influenza